Adherence to generic reverse transcriptase inhibitor-based antiretroviral medication at a Tertiary Center in North India

AIDS and Behavior

Volumn 11, Issue 1, 2007, Pages 99-102

  Wanchu, A ^a   Kaur, R ^a   Bambery, P ^a   Singh, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Adherence; Antiretrovirals; HIV; India; Resource constrained

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE FINANCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUESTIONNAIRE; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33846463847     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-006-9101-y     Document Type: Article

References (18)

1. Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33, 1417-1423.
2. Anon. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Retrieved June 5, 2005, from http: //AIDSinfo.nih.gov
3. Bartlett, J. A. (2002). Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndrome, 29(Suppl. 1), S2-S10.
4. Casado, J. L., Perez-Elias, M. J., Antela, A., Sabido, R., Marti-Belda, P., Dronda, F., et al. (1998). Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS, 12, F131-F135.
5. Dybul, M., Nies-Kraske, E., Dewar, R., Maldarelli, F., Hallahan, C. W., Daucher, M., et al. (2004). A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. Journal of Infectious Diseases, 189, 1974-1982.
6. Fang, C. T., Hsu, H. M., Twu, S. J., Chen, M. Y., Chang, Y. Y., Hwang, J. S., et al.; Division of AIDS and STD, Center for Disease Control, Department of Health, Executive Yuan. (2004). Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. Journal of Infectious Diseases, 190, 879-885.
7. Montaner, J. S., Hogg, R. S., Weber, A. E., Anis, A. H., O'Shaughnessy, M. V., and Schechter, M. T. (1998). Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. Journal of American Medical Association, 279, 450-454.
8. Knobel, H., Guelar, A., Carmona, A., Espona, M., Gonzalez, A., Lopez-Colomes, J. L., et al. (2001). Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care and STDS, 15, 193-199.
9. Kumarasamy, N., Vallabhaneni, S., Flanigan, T. P., Balakrishnan, P., Cecelia, A., Carpenter, C. C., et al. (2005). Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS, 19, 625-627.
10. Laurent, C., Kouanfack, C., Koulla-Shiro, S., Nkoue, N., Bourgeois, A., Calmy, A., et al. (2004). Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected in Cameroon: Open-label multicentre trial. Lancet, 364, 29-34.
11. Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134, 968-977.
12. Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., Arici, C., et al. (2005). Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40, 158-163.
13. Nieuwkerk, P. T., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., et al.; ATHENA Project. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine, 161, 1962-1968.
14. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853-860.
15. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
16. Turner, B. (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. Clinical Infectious Diseases, 185(Suppl. 2), S143-S151.
17. WHO, UNAIDS. (2003). Treating 3 million by 2005: Making it happen - the WHO strategy. Geneva: World Health Organization. Retrieved May 4, 2005, from http://www.who.int/3by5/ publications/documents/en/ 3by5StrategyMakingItHappen.pdf
18. WHO. (2003). Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach-2003 revision. Geneva: World Health Organization. Retrieved May 4, 2005, from http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf